The Hunger Code

The Discovery

The Drug That Arrived in the Wrong Decade

The GLP-1 story begins not in a laboratory, but in an intestine. GLP-1 is a hormone naturally produced by L-cells lining the small intestine. It is released after eating and acts on the pancreas to stimulate insulin secretion and suppress glucagon. It is one of the body's oldest and most reliable signals: you have eaten, stop being hungry.

The problem researchers faced for decades was that GLP-1 has a natural half-life of approximately 2 minutes. The enzyme DPP-4 degrades it almost immediately, which is why the hunt for long-acting analogues consumed medicinal chemists for years. The payoff came slowly: exenatide in 2005, liraglutide in 2010, semaglutide in 2017 for diabetes. Each iteration was better, but it took Novo Nordisk's reformulation of semaglutide at a higher dose—2.4mg weekly—approved as Wegovy in 2021, to create what the public now calls the "Ozempic moment."

But the weight-loss story, it turned out, was only the beginning. In clinical trials, something was happening that the researchers hadn't fully anticipated. Patients reported not just eating less, but losing the desire to eat. The mental noise of hunger—the constant background hum of craving, the negotiations between impulse and restraint—had quieted in a way they hadn't experienced before. It was not simply satiety. It was something closer to indifference to food itself.

And then came the reports from the reward circuits. The same drug that had muted hunger for food seemed to mute hunger for other things. This was not in any protocol. This was medicine discovering itself, live, in the data.

The Biology

What GLP-1 Does to the Brain

For decades, GLP-1 was understood as a peripheral hormone—something made in the gut, acting on the pancreas and other organs. Then researchers began mapping where GLP-1 receptors actually live, and the field's entire understanding shifted. These receptors are not confined to the digestive system. They are scattered throughout the brain, in places that control hunger, reward, memory, and inflammation.

The arcuate nucleus of the hypothalamus is the body's central hunger-regulation circuit. It is small—only a few millimeters across—but it contains two populations of neurons locked in constant biological combat. One population, the NPY/AgRP neurons, drives hunger: they increase appetite, boost energy expenditure, and whisper eat more. The other, the POMC/CART neurons, suppress hunger: they reduce food intake and whisper you are full. GLP-1 receptor activation tips this balance decisively. It suppresses NPY/AgRP while enhancing POMC/CART. The result is not simply feeling full after a meal. It is a sustained shift in the tug-of-war itself, reducing the drive to eat across the entire day.

But the hypothalamus is not the only place these receptors live. In the brainstem, there is a small region called the area postrema—it sits outside the blood-brain barrier, allowing it to directly sample circulating hormones. When GLP-1 arrives there, it relays satiety signals downstream to the nucleus tractus solitarius, which passes them to the hypothalamus. It is a multi-layer system, redundancy built in, as if the body has been expecting this intervention all along.

And then there are the reward circuits. GLP-1 receptors are present in the dopaminergic reward pathways—the ventral tegmental area (VTA) and nucleus accumbens—the same neural real estate involved in substance addiction and compulsive behavior. Activation of GLP-1 receptors in these regions reduces the reward value of food. But reward circuitry does not distinguish between food and other rewarding stimuli. The same receptor suppresses the perceived reward value of alcohol, cocaine, nicotine, and opioids. This explains the unprompted clinical observations: the drug was doing exactly what it was supposed to do in the reward circuit, and those circuits didn't distinguish between food and other things people crave.

It is a single receptor, hitting multiple targets across the brain, each with profound consequences. For the first time, medicine had a tool that could modulate hunger, reward-seeking, and potentially neuroinflammation all through the same biological switch.

The Evidence

From Cardiovascular Disease to Alzheimer's

The SELECT trial stands as one of the largest and most rigorous tests of any obesity drug ever conducted. Seventeen thousand, six hundred and four patients with overweight or obesity but no diabetes, across 41 countries, followed for an average of 39.8 months. Published in the New England Journal of Medicine in 2023. The result: a 20 percent reduction in major adverse cardiovascular events—heart attack, stroke, or cardiovascular death—compared to placebo.

But the timing was what caught the field's attention. Within the first three months of treatment, patients showed a 38 percent reduction in major adverse cardiovascular events. Within six months, 41 percent. At these timepoints, most patients had not yet lost significant weight, and many were not yet at the full dose. This suggested something other than weight loss alone was at work. Further analysis revealed that only 33 percent of the cardiovascular benefit could be explained by changes in weight or waist circumference. The majority of the effect—a direct biological action on cardiovascular and inflammatory systems—was independent of what the scales showed.

On addiction: multiple independent observational reports now document patients describing reduced or eliminated cravings for alcohol, cocaine, nicotine, and opioids while taking GLP-1 agonists—effects they hadn't sought and often hadn't been told to expect. These are not controlled trials; they are early signals. But the consistency of the reports has spurred formal research. Controlled trials investigating GLP-1 agonists for substance use disorders are now underway.

On neurodegeneration: liraglutide's Phase 2b trial, published in Nature Medicine in 2025, provided the first clinical evidence that a GLP-1 drug can slow cognitive decline in Alzheimer's disease. The mechanism appears to involve reduced neuroinflammation and reduced amyloid burden—both preclinical evidence and early clinical data point in this direction. The field is now focused on a larger trial: EVOKE and EVOKE+, enrolling approximately 1,800 patients with early-stage Alzheimer's disease on semaglutide. Enrollment began in 2021. Results are expected in late 2025. This is the trial neurology is watching.

There is even early evidence of benefit in Parkinson's disease. GLP-1 receptors have been found on dopamine-producing neurons in the substantia nigra—the very region damaged in Parkinson's. Animal models suggest neuroprotective effects. Human trials have not yet begun, but the hypothesis is sound.

The Implications

One Receptor, Three Epidemics

The GLP-1 story is teaching medicine something it has been slow to learn: that hunger, addiction, and neurodegeneration are not as separate as the medical specialties treating them. They share biological architecture. The gut produces a hormone. That hormone activates receptors in the brain's hunger circuits, its reward circuits, and its inflammatory pathways. Dysregulation of this system—through diet, sedentary behavior, chronic stress, or genetic variation—appears to contribute to metabolic disease, addiction, and cognitive decline through the same molecular pathway.

We have found a single receptor that connects three of the most costly epidemics in modern medicine. We have, for the first time, a drug that activates it systemically. The implications are only beginning to be understood.

But there is a shadow side to this story that must be named: access. GLP-1 drugs currently cost approximately $1,000 per month in the United States without insurance coverage. This is not a drug reaching most of the world yet. The equity gap between those who can access these medicines and those who cannot is widening daily. For a person in a low-income country, GLP-1 drugs remain inaccessible—not because they are ineffective, but because they are too expensive.

The patent situation offers a glimmer of hope. Semaglutide's core patents are expected to expire around 2032, opening the door to generic manufacturing at dramatically lower cost. This could transform access in lower-income countries. The question is whether regulatory and manufacturing infrastructure will be ready to capitalize on that window.

Meanwhile, the next generation is already in development. Oral formulations of semaglutide are being refined—removing the need for weekly injections. Tirzepatide, a dual GLP-1 and GIP agonist, is showing greater weight loss than semaglutide alone. And triple agonists, targeting GLP-1, GIP, and glucagon receptors simultaneously, are in early trials. Each iteration is more potent, more nuanced, more precisely targeted.

The story of GLP-1 is not finished. It may have barely started.